Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
4.84B
Market cap4.84B
Price-Earnings ratio
-8.73
Price-Earnings ratio-8.73
Dividend yield
—
Dividend yield—
Average volume
6.55M
Average volume6.55M
High today
$29.35
High today$29.35
Low today
$27.25
Low today$27.25
Open price
$27.30
Open price$27.30
Volume
5.95M
Volume5.95M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$27.25
52 Week low$27.25

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $28.90. The company's market cap stands at 4.84B, with a P/E ratio of -8.73.

On 2026-11-15, Ionis Pharmaceuticals(IONS) stock moved within a range of $27.25 to $29.35. With shares now at $28.90, the stock is trading +6.1% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 5.95M, compared to an average daily volume of 6.55M.

The stock's 52-week range extends from a low of $27.25 to a high of $86.74.

The stock's 52-week range extends from a low of $27.25 to a high of $86.74.

IONS News

TipRanks 22h
Ionis Pharmaceuticals Earnings Call Signals Growth Amid Setbacks

Ionis Pharmaceuticals Inc. ((IONS)) has held its Q3 earnings call. Read on for the main highlights of the call. Ionis Pharmaceuticals’ earnings call carried a...

Simply Wall St 1d
Ionis Stock Is Up 6.4% What's Changed After Two Year HAE Data

Ionis Pharmaceuticals reported Q3 2026 revenue of US$242.72 million and a net loss of US$109.97 million, and reaffirmed full year revenue guidance of US$875 mil...

Ionis Stock Is Up 6.4% What's Changed After Two Year HAE Data
TipRanks 3d
Ionis Pharmaceuticals presents new long-term data on DAWNZERA

Ionis Pharmaceuticals (IONS) announced new long-term data for DAWNZERA, the first and only RNA-targeted medicine for hereditary angioedema, to be presented at t...

Analyst ratings

88%

of 26 ratings
Buy
88.5%
Hold
11.5%
Sell
0%

More IONS News

Simply Wall St 5d
Ionis Pharmaceuticals Could Be 67% Below Fair Value As TRYNGOLZA Outlook Resets

Ionis Pharmaceuticals (IONS) reset expectations around its triglyceride drug TRYNGOLZA after a slower than hoped commercial ramp, trimming 2026 sales guidance w...

Ionis Pharmaceuticals Could Be 67% Below Fair Value As TRYNGOLZA Outlook Resets
Simply Wall St 6d
What Does Ionis Pharmaceuticals TRYNGOLZA Forecast Cut Mean For Growth?

Ionis Pharmaceuticals (NasdaqGS:IONS) cut its full-year TRYNGOLZA sales forecast by roughly 50% after a slower-than-expected launch. Management cited challenge...

What Does Ionis Pharmaceuticals TRYNGOLZA Forecast Cut Mean For Growth?
The Motley Fool 6d
Ionis: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Ionis (IONS -21.36%) lowered its full-year TRYNGOLZA revenue guidance to approximately $50 millio...

Ionis: 3 Key Takeaways for Long-Term Investors
Benzinga 6d
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance. • Ionis...

Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
Investor's Business Daily 6d
Ionis Pharma Is Poised To Slam Into A 19-Month Low. Here's Why.

Technology Ionis Pharma Is Poised To Slam Into A 19-Month Low. Here's Why. Licensing Sales of Ionis Pharmaceuticals' (IONS) triglycerides-lowering drug, Tryngol...

Ionis Pharma Is Poised To Slam Into A 19-Month Low. Here's Why.
Zacks 7d
Ionis Pharmaceuticals Reports Q3 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS Quick QuoteIONS - Free Report) reported $243 million in revenue for the quarter ended September 2026, representing a year-over...

Ionis Pharmaceuticals Reports Q3 Earnings: What Key Metrics Have to Say
TipRanks 7d
Ionis: TRYNGOLZA’s Early Market Lead Supports Buy Rating; $100 Price Target Unchanged

Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The result...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.